Mitogen information summaries

Cancer Biotherapy and Radiopharmaceuticals

Volumn 17, Issue 5, 2002, Pages 569-597

  Wimer, Bruce M ^a   Mann, Paul L ^b  

^a JBMW Immunotherapeutics   (United States)

^b Protalex Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANDROGEN; ANTIRETROVIRUS AGENT; AZATHIOPRINE; CHLORAMPHENICOL; CONCANAVALIN A; IMATINIB; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; MITOGENIC AGENT; PHYTOHEMAGGLUTININ; POKEWEED MITOGEN; PREDNISONE;

ACUTE LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADULT RESPIRATORY DISTRESS SYNDROME; ANAPHYLAXIS; APLASTIC ANEMIA; BONE PAIN; CANCER; CAPILLARY LEAK SYNDROME; CHILL; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DRUG MEGADOSE; ERYTHROCYTE APLASIA; FEVER; GLIOMA; GRAFT VERSUS HOST REACTION; HANTAVIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; IMMUNOMODULATION; IMMUNOSTIMULATION; KIDNEY CARCINOMA; KIDNEY GRAFT REJECTION; LEG PAIN; LEUKOCYTE TRANSFUSION; MALAISE; MELANOMA; MITOGENESIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN TEST; THORAX PAIN; VIRUS INFECTION; VOMITING;

EID: 0036030352     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497802760804808     Document Type: Review

References (99)

1. Wimer BM. The rationale of using phytohemagglutinin (PHA) as both adoptive cell activator and host immunopotentiator for immunotherapy of hematologic malignancies. In: Rich MA, Yohn DS (eds): Leukemia Reviews International. vol. 1, Advances in Comparative Leukemia Research. New York, Marcel Dekker, Inc., 1983, pp. 264-265.
2. Landsteiner K. The Specificity of Serological Reactions. Charles Thomas, Springfield, 1936.
3. Hungerford DA, Donnelly AJ, Nowell PC, Beck S. The chromosome constitution of a human phenotypic intersex. Am J Hum Genet 1959;11:215-236.
4. Nowell PC. Phytohemagglutinin: An initiator of mitosis in cultures of human leukocytes. Cancer Res 1960;20:362-426.
5. Naspitz CK, Richter M. The action of phytohemagglutinin in vivo and in vitro, A review. Prog Allergy 1968;12:1-85.
6. Wimer BM. The ideal biological response modifier. Mol Biother 1989;1:311-317.
7. Wimer BM. Characteristics of PHA-L4 the mitogenic isolectin of phytohemagglutinin as an ideal biological response modifier (BRM). Mol Biother 1990;2:4-17.
8. Wimer BM. Therapeutic activities of PHA-L4 the mitogenic isolectin of phytohemagglutinin. Mol Biother 1990;2:74-90.
9. Wimer BM. Potential therapeutic applications of PHA-L4 the mitogenic isolectin of phytohemagglutinin. Molecular Biother 1990;2:196-200.
10. Wimer BM. The rationale of mitogenic lectin therapy for cancer. In: Gabius H-J, Gabius S (eds): Lectins and Cancer. Berlin-Heidelberg-New York-Tokyo, Springer-Verlag, 1991, pp. 217-228.
11. Wimer BM. Haplotype donor-generated graft-versus-leukemia responses: Serendipity revisited. Cancer Biother 1995;10:181-194.
12. Wimer BM. Putative effects of mitogenic lectin therapy corroborated by alloactivation data. Cancer Biother Radiopharm 1996;11:57-75.
13. Wimer BM. Therapeutic immunostimulating effects of plant mitogens exemplified by the L4 isolectin of PHA. Cancer Biother Radiopharm 1997;12:195-212.
14. Wimer BM, Morris RE. Theoretical benefits of mitogen applications for HIV-1 infections. Cancer Biother Radiopharm 1997;12:213-222.
15. Wimer BM. Immunosuppressive applications of PHA and other plant mitogens. Cancer Biother Radiopharm 1998;13:99-107.
16. Wimer BM. PHA for aplastic anemias: The alpha but not the omega of mitogen therapies. Cancer Biother Radiopharm 1998;13:109-120.
17. Wimer BM. Implications of the analogy between recombinant cytokine toxicities and manifestations of hantavirus infections. Cancer Biother Radiopharm 1998;13:193-207.
18. Wimer BM, Mann PL. Apparent pokeweed mitogen cure of metastatic gum melanoma in an older dog. Cancer Biother Radiopharm 2000;15:201-205.
19. Wimer BM. Mitogen hypotheses revisited: Enhancement of allograft tolerance and replacement of transplantation procedures in treating cancer. Cancer Biother Radiopharm 2000;15:207-209.
20. Rigas DA, Tisdale VV. Bioassay and dose-response of the mitogenic activity of the phytohemagglutinin Phaseolus vulgaris. Experientia 1969;25:399-400.
21. Rigas DA, Head C. The dissociation of phytohemagglutinin of Phaseolus vulgaris by 8.0 M urea and the separation of the mitogenic from the erythroagglutinating activity. Biochem Biophys Res Commun 1969;34:633-639.
22. Allen LW, Svenson RH, Yachnin S. Purification of mitogenic proteins derived from Phaseolus vulgaris: Isolation of potent and weak phytohemagglutinins possessing mitogenic activity. Proc Natl Acad Sci U S A 1969;63:334-341.
23. Yachnin S, Svenson RH. The immunological and physiochemical properties of mitogenic proteins derived from Phaseolus vulgaris. Immunology 1972;22:871-883.
24. Miller JB, Hsu R, Heinrikson R, Yachnin S. Extensive homology between the subunits of the phytohemagglutinin mitogenic proteins derived from Phaseolus vulgaris. Proc Natl Acad Sci U S A 1975;72:1388-1391.
25. Weber TH. Isolation and characterization of a lymphocyte-stimulating leucoagglutinin from red beans (Phaseolus vulgaris). Scand J Clin Lab Invest 1969; Suppl 111: 1-80.
26. Weber TH, Lindahl-Kiessling K, Mattsson A, Alm GV. Autoradiographic studies of lymphocytes stimulated in vitro with tritium labeled kidney bean leucoagglutinin. Life Sci 1972;11:343-350.
27. Weber T. Kinetics of the reaction of kidney-bean leucoagglutinin with human lymphocytes. Experientia 1973;29:863-865.
28. Räsänen V, Weber TH, Gräsbeck R. Crystalline kidney-bean leucoagglutinin. Eur J Biochem 1973;38:193-200.
29. Leavitt RD, Felsted RL, Bachur NR. Biological and biochemical properties of Phaseolus vulgaris isolectins. J Biol Chem 1977;252:2961-2966.
30. Felsted RL, Egorin MJ, Leavitt RD, Bachur NR. Recombinations of subunits of Phaseolus vulgaris isolectins. J Biol Chem 1977;252:2967-2971.
31. Glad C, Borrebaeck CAK. Affinity of phytohemagglutinin (PHA) for serum proteins and regulation of the lectin-induced lymphocyte transformation. J Immunol 1984;133:2126-2132.
32. Fleischmann G, Mauder I, Illert W, Rudiger H. A one-step procedure for isolation and resolution of Phaseolus vulgaris isolectins by affinity chromatography. Biol Chem Hoppe-Seyler 1985;366:1029-1032.
33. Kanellopoulos JM, De Petris S, Leca G, Crumpton MJ. The mitogenic lectin from Phaseolus vulgaris does not recognize the T3 antigen of human T lymphocytes. Eur J Immunol 1985;15:479-486.
34. Hoffman LM, Donaldson DD. Synthesis of mitogenic phytohemagglutinin-L in Escherichia coli. Biotechnology 1987;5:157-160.
35. Hoffman LM. Method and composition for producing lectin in microorganisms. United States Patent 4,870,015, Sept. 26, 1989.
36. Lindahl-Kiessling K. Mechanism of phytohemagglutinin (PHA) action. V. PHA compared with concanavalin A (Con A). Exp Cell Res 1972;70:17-26.
37. Lewis MG, Humble JG, Lee ES, Phillips TM. The effects of intravenous phytohaemagglutinin in a patient with disseminated malignant melanoma. A clinical and immunological study. Rev Eur Etudes Clin Biol 1971;16:924-927.
38. Aksoy M, Erdem S, Dincol K. Phytohaemagglutinin in refractory anaemia. Lancet 1966;2:1464-1465.
39. Zuckerman KS, LoBuglio AF. Phytohemagglutinin skin tests in cancer patients. Cancer 1977;39:2355-2361.
40. Wimer BM, Mann PL. Advantages of mitogen immunotherapy for HIV infections exemplified by phytohemagglutinin and pokeweed mitogen. Cancer Biother & Radiopharm 2000;15:629-644.
41. Wimer BM. Update: Mitogens for curative therapy of HIV-1 infections. Cancer Biother Radiopharm 2002;17:207-216.
42. Kolb HJ, Mittermüller J, Clemm CH, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-2465.
43. van Rhee F, Lin F, Cullis JO, Spencer A, Cross NC, Chase A, Garicochea B, Bungey J, Barrett J, Goldman JM. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994;83:3377-3383.
44. Kolb H-J, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041-2050.
45. Collins RH, Spilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433-444.
46. Mathé G, Amiel JL, Schwarzenberg L, Cattan A, Schneider M. Adoptive immunotherapy of acute leukemia: Experimental and clinical results. Cancer Res 1965;25:1525-1531.
47. Mathé G, Schwarzenberg L, Amiel JL, Schneider M, Cattan A, Schlumberger JR. The role of immunology in the treatment of leukemias and hematosarcomas. Cancer Res 1967;27:2542-2553.
48. Schwarzenberg L, Mathé G, Amiel JL, Cattan A, Schneider M, Schlumberger JR. Study of factors determining the usefulness and complications of leukocyte transfusions. Am J Med 1967;43:206-213.
49. Mathé G, Amiel JL, Schwarzenberg L. Leukocyte transfusions. In: Mathé G, Schwarzenberg L (eds): Bone Marrow Transplantation and Leukocyte Transfusions, Springfield, CC Thomas, 1971, pp. 104-130.
50. Mathé G, Amiel JL, Schwartzenberg L, Schneider M, Cattan A, Schlumberger JR, Hayat M, de Vassal F. Active immunotherapy for acute lymphoblastic leukemia. Lancet 1969;1:697-699.
51. Mathé G, Florentin I, Bruley-Rosset M, Kiger N, Ollson L. Systemic immunotherapy of cancer minimal residual disease: Clinical status and new experimental data approaches. In: Jones SE and Salmon SE (eds): Adjuvant Therapy of Cancer II. New York, Grune & Stratton, 1979, pp. 79-86.
52. Craddock CG. Kinetics of lymphoreticular tissue, with particular emphasis on the lymphatic system. Semin Hematol 1967;4:387-414.
53. Heiniger HJ, Feinendegen LE, Bürki K. Reutilization of thymidine in various groups of rat bone marrow cells. Blood 1971;37:340-348.
54. Wimer BM. Remission of lymphoblastic leukemia. Lancet 1976;1:316.
55. Pineda AA, Hoagland HC. Unpublished Observations. Personal communication, 1977.
56. Berke G. The functions and mechanisms of action of cytolytic lymphocytes. In: Paul WE (ed): Fundamental Immunology, 3rd ed. New York, Raven Press Ltd, 1993, pp. 969.
57. Mazumder A, Grimm EA, Rosenberg SA. Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization. Cancer Immunol Immunother 1983;15:1-10.
58. Mazumder A, Grimm EA, Rosenberg SA. Characterization of the lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with phytohemagglutinin. J Immunol 1983;130:958-964.
59. Mazumder A, Grimm EA, Zang HZ, Rosenberg SA. Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins. Cancer Res 1982;42:913-918.
60. Hunninghake GW, Fauci AS. Lymphocyte-mediated cytotoxicity against human allogeneic and autologous lymphocyte targets after Con A activation of cytotoxic effector cells. J Immunol 1977;119:1122-1128.
61. Vijayakumar T, Remani P, Ankathil R, Bhattathiri VN. Plant lectins in immunology, cytology and hematology: A bibliography, and projects for development. Hematol Rev Commun 1994;8:151-168.
62. Calne RY, Wheeler JR, Hum BAL. Combined immunosuppressive action of phytohaemagglutinin and azathioprine (Imuran) in dogs with renal transplants. Br Med J 1965;2:154-155.
63. Gertner HR Jr, Harrah JD, Sample WF, Chretien, PB. Effect of phytohemagglutinin-P on immunosuppressive regimens in the adult dog. Surg Forum 1969;20:254-256.
64. Wimer BM. Mitogen therapy for biological warfare/terrorist attacks and viral hemorrhagic fever control. Cancer Biother Radiophann 2002;17:23-36.
65. Buschor OR, von Deschwanden PL. Phytohaemagglutinin in aplastic anaemia. Lancet 1966;1:770-771.
66. Allison A, Hume R, Shaw G, Whitelaw J, Willoughby M. Phytohaemagglutinin in refractory anaemia. Scott Med J 1965;10:461-465.
67. Machado EA, Lozzio BB, Chemoff AI. Functional and cellular alterations produced by phytohemagglutinin. II. Depression of antibody formation and proliferation of lymphopoietic system. Arch Pathol 1969;88:118-129.
68. Schiavino D, Nucera E, Murzilli F, Schinco G, Papa G, Fais G, Patriarca G. Anaphylactic shock after skin test with phytohaemagglutinin. Allergy 1992;47:121-122.
69. Goldberg ML, Rosenau W, Burke GC. Fractionation of phytohemagglutinin. I. Purification of the RNA and DNA synthesis-stimulating substances and evidence that they are not proteins. Proc Natl Acad Sci U S A 1969;64:283-289.
70. Goldberg ML, Rosenau W, Burke GC, Moon HD. Dose-response of lymphocytes to purified, protein-free phytohemagglutinin: Lack of metabolic inhibition with increasing concentrations. Proc Soc Exp Biol Med 1970;13:459-461.
71. Rosenau W, Habler J, Goldberg M. Prolongation of skin graft survival by administration of purified phytohemagglutinin. Transplantation 1972;13:624-626.
72. Mann PL, Eschima D, Bitner DM, Griffey RH, Wenk R, Bom JL, Matwiyoff NA. Biomodulation: An integrated approach to access and manipulate biological information. In: Gabius H-J, Gabius S (eds): Lectins and Cancer. Berlin-Heidelberg-New York-Tokyo, Springer-Verlag, 1991, pp. 179-206.
73. Morris RE, Director, Laboratory for Transplantation Immunology, Department of Cardiovascular Surgery, Stanford University Medical Center, Personal communication, 1991.
74. National Cancer Institute. Unpublished report communicated to RE Morris, 1990.
75. Morris RE, Director, Laboratory for Transplantation Immunology, Department of Cardiovascular Surgery, Stanford University Medical Center, Personal communication, 1991.
76. Morris RE, Hoyt G, DeValeria P. A comparison of the in vitro and in vivo immunologic activities of concanavalin A and its succinylated derivative. Transplant Proc 1987;19:626-627.
77. Robinson WE, Montefiori DC, Mitchell WM. Evidence that mannosyl residues are involved in human immunodeficiency virus type 1 (HIV-1-1) pathogenesis. AIDS Res Hum Retroviruses 1987;3:265-282.
78. Lifson J, Coutré S, Huang E, Engleman E. Role of envelope glycoprotein carbohydrate in human immunodeficiency virus (HIV-1) infectivity and virus-induced cell fusion. J Exp Med 1986;164:2101-2106.
79. Morris RE. Concanavalin A dimers as therapeutic agents. United States Patent 4,889,842, Dec. 26, 1989.
80. Busse WW, Swenson CA, Sharpe G, Koschat M. Enhanced basophil histamine release to concanavalin A in allergic rhinitis. J Allergy Clin Immunol 1986;78:90-97.
81. Waxdal MJ. Isolation, characterization, and biological activities of five mitogens from pokeweed. Biochemistry 1974;13:3671-3677.
82. Yokoyama K, Yano O, Terao T, Osawa T. Purification and biological activities of pokeweed (Phytolacca americana) mitogens. Biochim Biophys Acta 1976;427:443-452.
83. Börjeson J, Reisfeld R, Chessin LN, Welsh PD, Douglas SD. Studies on human peripheral blood lymphocytes in vitro. I. Biological and physiochemical properties of the pokeweed mitogen. J Exp Med 1966;124:859-872.
84. Fames P, Barker BE, Brownhill LE, Fanger H. Mitogenic activity in Phytolacca americana (pokeweed). Lancet 1964;2:1000-1001.
85. Barker BE, Farnes P, Fanger H. Mitogenic activity in Phytolacca americana (pokeweed). Lancet 1965;1:170.
86. Barker BE, Farnes P, LaMarche PH. Peripheral blood plasmacytosis following systemic exposure to Phytolacca americana (pokeweed). Pediatrics 1966;38:490-493.
87. Mann PL. Unpublished observations, 1978.
88. Jadus MR, Schmunk G, Djeu JY, Parkman R. Morphology and lytic mechanisms of interleukin 3-dependent natural cytotoxic cells: Tumor necrosis factor as a possible mediator. J Immunol 1986;137:2774-2783.
89. Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature 1990;346:274-276.
90. Broudy VC. Stem cell factor and hematopoiesis. Blood 1997;90:1345-1364.
91. Alibek K, Handelman S. Biohazard. Dell Publishing: Random House, Inc., New York, 1999, 322 pp.
92. Yang Z, Delgado R, Xu L, Todd RF, Nabel EG, Sanchez A, Nabel GJ. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science 1998;279:1034-1037.
93. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 2000;6:886-889.
94. Barry M. III. Viral hemorrhagic fevers (Viral disease in hematology). In: Schechter GP, Berliner N, Telen MJ (eds): Hematology 2000: The American Society of Hematology Education Program Book, San Francisco, CA, December 1-5, 2000, pp. 414-421, 423.
95. Harden B. Dr. Matthew's passion. The New York Times Magazine, Feb. 18, 2001, pp. 1-20.
96. Jones RJ. II. Differentiation therapy revisited (New developments in the therapy of acute myelocytic leukemia, NC Gorin, Chair). In: Schechter GP, Berliner N, Telen MJ (eds): Hematology 2000 American Society of Hematology Education Program Book, San Francisco, CA; 2000, pp. 74-76, 106-109.
97. Sachs L. The molecular control of hematopoiesis and leukemia. Hamm-Wasserman Lecture. In Schechter GP, Berliner N, Telen MJ, (eds). L Hematology 2000 American Society of Hematology Education Program Book, San Francisco, CA, 2000, p. 1.
98. Kantarjian HM, Talpaz M. V. STI571 in chronic myelogenous leukemia (Chronic myelogenous leukemia: Disease biology and current and future therapeutic strategies, H Kantarjian, Chair). In: Schechter GP, Berliner N, Telen MJ (eds). Hematology 2000 American Society of Hematology Education Program Book, San Francisco, CA, 2000, pp. 105-106, 106-109.
99. Goldman JM, Druker BJ. Chronic myeloid leukemia: Current treatment options. Blood 2001;98:2039-2042.